Severe adverse events associated with use include acute pancreatitis, thyroid abnormalities, gastroparesis, ileus, bowel obstruction, gallbladder disease, and allergic reactions
Overview : While rare, some users report mood changes or depressive symptoms with semaglutide
Retatrutide has not received MHRA or EMA marketing authorisation and must only be used within a registered clinical trial or an approved early-access programme under direct medical supervision
Tirzepatide most recently came off the shortage list in December 2024, while semaglutide was removed in February 2025
Faecal elimination is minimal, accounting for only small amounts of metabolites (Zyvox, 2014
As compounders, we specialize in the sublingual delivery of medications for hormone replacement therapy and pediatrics